Metagenomi, Inc. (MGX) Price & Analysis

Compare

915 Followers

MGX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.23 - $4.92

Previous CloseN/A

Volume382.73K

Average Volume (3M)758.08K

Market Cap

$71.31M

Enterprise Value-$107.01M

Total Cash (Recent Filing)$204.99M

Total Debt (Recent Filing)$42.99M

Price to Earnings (P/E)―

Beta1.05

Next Earnings

Nov 12, 2025

EPS Estimate

-0.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding37,533,134

10 Day Avg. Volume423,832

30 Day Avg. Volume758,084

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.50

Enterprise Value/Revenue-3.17

Enterprise Value/Gross Profit-3.17

Enterprise Value/Ebitda1.24

Forecast

1Y Price Target

$4.50

Price Target Upside141.94% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Partnerships And CollaborationsPartnerships continue to progress with nomination of 1-2 DCs from the IONS collaboration expected, showing active collaboration efforts.

Pipeline DevelopmentAdditional internal and partnered programs are progressing, with preclinical proof of concept achieved in several areas, showcasing a broad development pipeline.

Research And DevelopmentMGX highlighted NHP durability data from the hemophilia A program, demonstrating sustained FVIII activity in treated subjects, indicating promising results.

Bears Say

EarningsMGX reported a net loss per share that was worse than the consensus estimate.

Financial PerformanceMGX reported a Q2 net loss of $19.9MM, pointing to financial challenges.

Metagenomi, Inc. News

Metagenomi price target lowered to $11 from $12 at Chardan

Chardan lowered the firm’s price target on Metagenomi (MGX) to $11 from $12. The firm updated its model...

2d ago

MGX

Metagenomi reports Q2 EPS (54c), consensus (61c)

Reports Q2 revenue $8.51M, consensus $7.72M. The company ended the quarter with $205.M in cash, cash equivalents, and...

5d ago

MGX

Metagenomi, Inc. Reports Q2 2025 Financial Results

Metagenomi, Inc. ( ($MGX) ) has released its Q2 earnings. Here is a breakdown of the information Metagenomi,...

4d ago

MGX

Metagenomi Reports Strong Q2 2025 Financial Results

Metagenomi, Inc. ( ($MGX) ) has shared an announcement. Metagenomi, Inc. reported its second quarter 2025 financial results...

5d ago

MGX

MGX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Metagenomi, Inc. (MGX) is scheduled to report 2nd quarter earnings on 08/13/2025. Regarding Q2 estimates, Wall Street analysts...

6d ago

MGX

Metagenomi, Inc. Holds Annual Stockholders Meeting

Metagenomi, Inc. ( ($MGX) ) just unveiled an announcement. On June 10, 2025, Metagenomi, Inc. held its annual...

2M ago

MGX

Metagenomi Reports Promising Hemophilia A Study Results

Metagenomi, Inc. ( ($MGX) ) has released its Q1 earnings. Here is a breakdown of the information Metagenomi,...

3M ago

MGX

Metagenomi Showcases Genome Editing Advances at ASGCT 2025

Metagenomi, Inc. ( ($MGX) ) has shared an announcement. On May 14, 2025, Metagenomi, Inc. announced the presentation...

3M ago

MGX

Metagenomi price target lowered to $16 from $20 at Wells Fargo

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Metagenomi (MGX) to $16 from $20 on...

3M ago

MGX

Metagenomi’s Promising Gene Editing Advancements and Strategic Growth Drive Buy Rating

TD Cowen analyst Joseph Thome has maintained their bullish stance on MGX stock, giving a Buy rating on...

3M ago

MGX

Metagenomi, Inc. Reports Q1 2025 Financial Results

Metagenomi, Inc. ( ($MGX) ) just unveiled an announcement. Metagenomi, Inc. announced its first quarter 2025 financial results...

3M ago

MGX

Metagenomi reports Q1 EPS (68c), consensus (51c)

Reports Q1 revenue $4.13M, consensus $7.96M. “We are excited about the transformative potential of our AI-driven metagenomi (MGX)cs...

3M ago

MGX

Metagenomi sees cash, equivalents supporting operations into 2027

16:35 EDT Metagenomi (MGX) sees cash, equivalents supporting operations into 2027 Published first on TheFly – the ultimate...

3M ago

MGX

Metagenomi price target lowered to $7 from $14 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Metagenomi (MGX) to $7 from $14 and...

5M ago

MGX

MGX FAQ

What was Metagenomi, Inc.’s price range in the past 12 months?

Metagenomi, Inc. lowest stock price was $1.23 and its highest was $4.92 in the past 12 months.

What is Metagenomi, Inc.’s market cap?

Metagenomi, Inc.’s market cap is $71.31M.

When is Metagenomi, Inc.’s upcoming earnings report date?

Metagenomi, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 87 days.

How were Metagenomi, Inc.’s earnings last quarter?

Metagenomi, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.619 by $0.079.

Is Metagenomi, Inc. overvalued?

According to Wall Street analysts Metagenomi, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Metagenomi, Inc. pay dividends?

Metagenomi, Inc. does not currently pay dividends.

What is Metagenomi, Inc.’s EPS estimate?

Metagenomi, Inc.’s EPS estimate is -0.57.

How many shares outstanding does Metagenomi, Inc. have?

Metagenomi, Inc. has 37,533,134 shares outstanding.

What happened to Metagenomi, Inc.’s price movement after its last earnings report?

Metagenomi, Inc. reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.619. Following the earnings report the stock price went up 3.191%.

Which hedge fund is a major shareholder of Metagenomi, Inc.?

Currently, no hedge funds are holding shares in MGX

Metagenomi, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-37.45%

Trailing 12-Months

Asset Growth

-29.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Metagenomi, Inc.

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Metagenomi, Inc. (MGX) Earnings & Revenues

Historic Earnings Reports

MGX Stock 12 Month Forecast

Average Price Target

$4.50

▲(141.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.25,2.6153846153846154,2.980769230769231,3.346153846153846,3.7115384615384617,4.076923076923077,4.442307692307692,4.8076923076923075,5.173076923076923,5.538461538461538,5.903846153846153,6.269230769230769,6.634615384615384,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.25,2.423076923076923,2.5961538461538463,2.769230769230769,2.9423076923076925,3.1153846153846154,3.2884615384615383,3.4615384615384617,3.6346153846153846,3.8076923076923075,3.980769230769231,4.153846153846153,4.326923076923077,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.25,2.230769230769231,2.2115384615384617,2.1923076923076925,2.173076923076923,2.1538461538461537,2.1346153846153846,2.1153846153846154,2.0961538461538463,2.076923076923077,2.0576923076923075,2.0384615384615383,2.019230769230769,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.97,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.11,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >